| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802936201012 | 293620101 | DORMIDEN PD.CSO.J.F 1MG/VIAL BTx(5 VIALSx1 MG) | 7.24 | 7.59 | 10.46 |
| 05/2018 | 2802936202019 | 293620201 | DORMIDEN PD.CSO.J.F 2MG/VIAL BTx(5 VIALSx2 MG) | 12.34 | 12.94 | 17.83 |
| 05/2018 | 2802936203016 | 293620301 | DORMIDEN PD.CSO.J.F 5MG/VIAL BTx(5 VIALSx5 MG) | 31.77 | 33.33 | 45.93 |
For use during the induction and maintenance of general anesthesia.
Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
1-20 minutes
Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.
* 350 mL/kg * 452 ± 144 mL/kg [neonates] * 223 ± 30.6 mL/kg [adolescents]
* 40 mL/min/kg [young, healthy adults]